ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
|Articles|February 25, 2021
Celonic to Establish New Cell and Gene Therapy Production Site in Switzerland
Author(s)BioPharm International Editors
The site will house development and GMP production capacities for cell and gene therapies, next-generation vaccines, and biopharmaceuticals, to support clients from early clinical trials through commercialization.
Advertisement
Celonic Group, a contract development and manufacturing organization (CDMO), announced on Feb. 25, 2021 that it has entered into a long-term lease agreement for a new production site and office space at the Novartis-operated Life Science Park Rheintal in Stein, Switzerland.
The 91,500-ft2 site will house development and GMP production capacities for cell and gene therapies, next-generation vaccines, and biopharmaceuticals, to support clients from early clinical trials through commercialization, Celonic said in a company press release. The expansion will be completed in two phases and will add up to 20 GMP cleanroom suites and offices, along with laboratories for process development, method development, and quality control services.
“This expansion to the Life Science Park Rheintal demonstrates our commitment to address the growing demand for cell and gene therapy manufacturing. With its unique location and on-site services, this state-of-the-art facility will further boost Celonic’s expansion into the cell and gene space and enable us to offer large-scale ATMP (advanced therapy medicinal products) GMP manufacturing from early 2022,” said Konstantin Matentzoglu, CEO of Celonic, in the press release. “We are looking forward to establishing a world-class cell and gene therapy facility in this fast-developing life sciences hub operated by Novartis.”
Source:
Advertisement
Related to this article
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5